ScholarLens Back to search
2010•Strait Pharmaceutical JournalRequires access

Controlled clinical trials of moxifloxacin in old patients with community-acquired pneumonia

Bin Wu

Open publisher page 0 citations

Abstract

OBJECTIVE To evaluate the efficiency and safety of moxifloxacin in old patients with community-acquired pneumonia(CAP).METHODS Aprospective design was conducted.80 old patients with CAP were randomly divided into trial group and control group.The 40 trial group members were treated with moxifloxacin.In the control group,40 patients were treated with levofloxacin and ceftriaxone sodium.Statistical difference was analyzedinterms effectiveness,side effects and the comparisons were made between the groups.RESULTS After treatment,the total cured rate for the trail group was 95%,while for the control group it was 77.5%;P0.05.The adverse drug reaction rates were evaluated in 80 patients,showing the rates were 7.5% and 10% respectively with no significant statistical differences(P0.05).CONCLUSION Moxifloxacin is effective and safe in the treatment of old patients with CAP.

About this research paper

What this paper is about

OBJECTIVE To evaluate the efficiency and safety of moxifloxacin in old patients with community-acquired pneumonia(CAP).METHODS Aprospective design was conducted.80 old patients with CAP were randomly divided into trial group and control group.The 40 trial group members were treated with moxifloxacin.In the control group,40 patients were treated with levofloxacin and ceftriaxone sodium.Statistical difference was analyzedinterms effectiveness,side effects and the comparisons were made between the groups.RESULTS After treatment,the total cured rate for the trail group was 95%,while for the control group it was 77.5%;P0.05.The adverse drug reaction rates were evaluated in 80 patients,showing the rates were 7.5% and 10% respectively with no significant statistical differences(P0.05).CONCLUSION Moxifloxacin is effective and safe in the treatment of old patients with CAP.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE To evaluate the efficiency and safety of moxifloxacin in old patients with community-acquired pneumonia(CAP).METHODS Aprospective design was conducted.80 old patients with CAP were randomly divided into trial group and control group.The 40 trial group members were treated with moxifloxacin.In the control group,40 patients were treated with levofloxacin and ceftriaxone sodium.Statistical difference was analyzedinterms effectiveness,side effects and the comparisons were made between the groups.RESULTS After treatment,the total cured rate for the trail group was 95%,while for the control group it was 77.5%;P0.05.The adverse drug reaction rates were evaluated in 80 patients,showing the rates were 7.5% and 10% respectively with no significant statistical differences(P0.05).CONCLUSION Moxifloxacin is effective and safe in the treatment of old patients with CAP.

Key concepts: Moxifloxacin, Medicine, Levofloxacin, Community-acquired pneumonia, Pneumonia, Internal medicine, Adverse effect, Clinical trial

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Controlled clinical trials of moxifloxacin in old patients with community-acquired pneumonia — Research Paper | ScholarLens